Poxel Signs a Strategic Partnership with Roivant to Develop and Commercialize Imeglimine

Overview


Emmanuelle Trombe (Paris) and Christine Wahr (Boston) advised French biopharmaceutical company Poxel SA on signing a strategic development and licensing agreement with global biopharmaceutical company Roivant Sciences for Poxel’s anti-diabetes drug Imeglimine in the United States, Europe and other countries.